Inmed Pharmaceuticals Stock Fundamentals

INM Stock  USD 5.26  0.11  2.14%   
InMed Pharmaceuticals fundamentals help investors to digest information that contributes to InMed Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of InMed Stock. The fundamental analysis module provides a way to measure InMed Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to InMed Pharmaceuticals stock.
At this time, InMed Pharmaceuticals' Cost Of Revenue is very stable compared to the past year. As of the 15th of December 2024, Total Operating Expenses is likely to grow to about 9.5 B, though EBIT is likely to grow to (7.3 M).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

InMed Pharmaceuticals Company Profit Margin Analysis

InMed Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Profit Margin

 = 

Net Income

Revenue

X

100

More About Profit Margin | All Equity Analysis

Current InMed Pharmaceuticals Profit Margin

    
  (1.67) %  
Most of InMed Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InMed Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition

InMed Pretax Profit Margin

Pretax Profit Margin

(0.72)

At this time, InMed Pharmaceuticals' Pretax Profit Margin is very stable compared to the past year.
Based on the latest financial disclosure, InMed Pharmaceuticals has a Profit Margin of -1.6694%. This is 85.11% lower than that of the Biotechnology sector and 92.75% lower than that of the Health Care industry. The profit margin for all United States stocks is 31.45% higher than that of the company.

InMed Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining InMed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare InMed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across InMed Pharmaceuticals competition to find correlations between indicators driving InMed Pharmaceuticals's intrinsic value. More Info.
InMed Pharmaceuticals is rated second overall in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, InMed Pharmaceuticals' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value InMed Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

InMed Profit Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InMed Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of InMed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing InMed Pharmaceuticals by comparing valuation metrics of similar companies.
InMed Pharmaceuticals is currently under evaluation in profit margin category among its peers.

InMed Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of InMed Pharmaceuticals from analyzing InMed Pharmaceuticals' financial statements. These drivers represent accounts that assess InMed Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of InMed Pharmaceuticals' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap2.2B1.2B879.5M45.4M38.2M1.8M
Enterprise Value2.1B1.2B874.0M36.9M32.5M1.9M

InMed Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, InMed Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to InMed Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

InMed Fundamentals

About InMed Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze InMed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InMed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InMed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-944 K-991.2 K
Total Revenue4.6 M4.8 M
Cost Of Revenue3.5 M3.7 M
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue1.1 K1.2 K
Research And Ddevelopement To Revenue 0.82  1.26 
Capex To Revenue 0.00  0.01 
Revenue Per Share 0.61  153.88 
Ebit Per Revenue(0.59)(0.62)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:
Check out InMed Pharmaceuticals Piotroski F Score and InMed Pharmaceuticals Altman Z Score analysis.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
230.4
Revenue Per Share
0.603
Quarterly Revenue Growth
(0.45)
Return On Assets
(0.39)
Return On Equity
(0.72)
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.